Related references
Note: Only part of the references are listed.Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression
Norbert Galldiks et al.
NEURO-ONCOLOGY (2020)
Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT
Antonia Dirnitrakopoulou-Strauss
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
3D models in the new era of immune oncology: focus on T cells, CAF and ECM
Francesca Di Modugno et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M. Gadgeel et al.
LUNG CANCER (2019)
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
Lucio Crino et al.
LUNG CANCER (2019)
The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal
Emilie Le Rhun et al.
NEURO-ONCOLOGY (2019)
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies
Ines Pires da Silva et al.
PIGMENT CELL & MELANOMA RESEARCH (2019)
Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM).
Gino Kim In et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
Hussein Abdul-Hassan Tawbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and efficacy of nivolumab plus ipilimumab (NIVO plus IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.
Hamid Emamekhoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
Chin-King Looi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous
Jarred P. Reed et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
Ronan Flippot et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Harriet M. Kluger et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Brain metastases
Achal Singh Achrol et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program
Sergio Bracarda et al.
FUTURE ONCOLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Imaging Criteria in Neuro-oncology
Martha Nowosielski et al.
SEMINARS IN NEUROLOGY (2018)
Emerging findings into molecular mechanism of brain metastasis
Wenting Ni et al.
CANCER MEDICINE (2018)
Expert opinion on pituitary complications in immunotherapy
Claire Briet et al.
ANNALES D ENDOCRINOLOGIE (2018)
A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin
Joseph Kattan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab
Sarah B. Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer
Shinkichi Takamori et al.
ANTICANCER RESEARCH (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Cancer immunotherapy-associated hypophysitis
Cinzia Solinas et al.
SEMINARS IN ONCOLOGY (2018)
Brain tumour post-treatment imaging and treatment-related complications
Alexander T. Kessler et al.
INSIGHTS INTO IMAGING (2018)
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma
Marc C. Chamberlain et al.
NEURO-ONCOLOGY (2017)
The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
Qingshui Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Advances in neuro-oncology imaging
Karl-Josef Langen et al.
NATURE REVIEWS NEUROLOGY (2017)
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
Daniel N. Cagney et al.
NEURO-ONCOLOGY (2017)
Current Clinical Brain Tumor Imaging
Javier E. Villanueva-Meyer et al.
NEUROSURGERY (2017)
Immune Checkpoint Inhibitors for Brain Metastases
Aaron C. Tan et al.
CURRENT ONCOLOGY REPORTS (2017)
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer
Rin Ogiya et al.
ONCOTARGET (2017)
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita et al.
SCIENTIFIC REPORTS (2017)
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
Sagun Parakh et al.
BRITISH JOURNAL OF CANCER (2017)
The Microenvironmental Landscape of Brain Tumors
Daniela F. Quail et al.
CANCER CELL (2017)
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment
Justine V. Cohen et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer
L. Tiffany Lyle et al.
CLINICAL CANCER RESEARCH (2016)
Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
Rovel J. Colaco et al.
JOURNAL OF NEUROSURGERY (2016)
The role of microglia and macrophages in glioma maintenance and progression
Dolores Hambardzumyan et al.
NATURE NEUROSCIENCE (2016)
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
Nathalie L. Albert et al.
NEURO-ONCOLOGY (2016)
Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases
Sied Kebir et al.
NEURO-ONCOLOGY (2016)
Updates in the management of brain metastases
Nils D. Arvold et al.
NEURO-ONCOLOGY (2016)
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
Paola Savoia et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Embracing rejection: Immunologic trends in brain metastasis
S. Harrison Farber et al.
ONCOIMMUNOLOGY (2016)
Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).
Jonathan Wade Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases
Alessandra Fabi et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
W. E. E. Eberhardt et al.
ANNALS OF ONCOLOGY (2015)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
R. Dummer et al.
ANNALS OF ONCOLOGY (2015)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
Jodi M. Saunus et al.
JOURNAL OF PATHOLOGY (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin et al.
LANCET ONCOLOGY (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Priscilla K. Brastianos et al.
CANCER DISCOVERY (2015)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
Ipilimumab and whole brain radiation therapy for melanoma brain metastases
Naamit K. Gerber et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Brain metastases following radical surgical treatment of non-small cell lung cancer: Is preoperative brain imaging important?
Emma L. O'Dowd et al.
LUNG CANCER (2014)
Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide
Sandra Coral et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
Dennis Lindau et al.
IMMUNOLOGY (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Expression of antigen processing and presenting molecules in brain metastasis of breast cancer
Yan Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
Anna Maria Di Giacomo et al.
LANCET ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Radiation-induced brain injury: a review
Dana Greene-Schloesser et al.
FRONTIERS IN ONCOLOGY (2012)
Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis
Toshihiro Seike et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Differential diagnosis by unenhanced FLAIR T2-weighted magnetic resonance images between solitary high grade gliomas and cerebral metastases appearing as contrast-enhancing cortico-subcortical lesions
Carmine Franco Muccio et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment
Dominique B. Hoelzinger et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force
R. Soffietti et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Share Paper
